AKT1 and colorectal carcinoma: Various drugs targeting this pathway are under investigation for CRC treatment, including pan-PI3K inhibitors, isoform-specific PI3K inhibitors, dual PI3K-mTOR inhibitors, Akt inhibitors, and mTOR inhibitors [126].